Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer

Inclusion Criteria: * Male age ≥ 40 years and candidate for radical prostate cancer treatment * Estimated life expectancy \> 8 years * At least one MRI-visible and biopsy-concordant tumor defined as Prostate Imaging-Reporting and Data System v2 (PI-RADS v2.1) ≥ 3 * Biopsy-confirmed, intermediate-risk localized prostate cancer: * Clinical or radiological tumor stage ≤ T2c, N0, M0 * ISUP GG 2 or 3 * Biopsy obtained ≥ 6 weeks and ≤ 12 months before treatment * PSA ≤ 20 ng/ml * No prior definitive treatment of prostate cancer * Eligible for MRI * Eligible for general anesthesia (American Society of Anesthesiologists Class III or less) * Patients taking 5-alpha reductase inhibitors (5-ARIs) are eligible if use is discontinued three months before and throughout the study period. * Informed consent: The patient must speak Finnish, English, or Swedish and must be able to understand the meaning of the study. The patient must be willing and able to sign the appropriate Ethics Committee (EC) approved informed consent documents in the presence of the designated staff. Exclusion Criteria: * Prior prostate cancer treatment with chemotherapy or hormonal therapy, including chemical or surgical castration, antiandrogen therapy, or androgen-receptor signaling inhibitors. * Relative or absolute contraindication to Degarelix * Severe, active cardiovascular comorbidity including unstable angina pectoris, congestive heart failure, deep vein thrombosis, pulmonary embolism, or myocardial infarcti…